Cargando…

Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials

The pharmacological treatment of postherpetic neuralgia (PHN) is unsatisfactory, and there is a clinical need for new approaches. Several drugs under advanced clinical development are addressed in this review. A systematic literature search was conducted in three electronic databases (Medline, Web o...

Descripción completa

Detalles Bibliográficos
Autores principales: Huerta, Miguel Á., Garcia, Miguel M., García-Parra, Beliu, Serrano-Afonso, Ancor, Paniagua, Nancy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455720/
https://www.ncbi.nlm.nih.gov/pubmed/37629168
http://dx.doi.org/10.3390/ijms241612987
_version_ 1785096520721235968
author Huerta, Miguel Á.
Garcia, Miguel M.
García-Parra, Beliu
Serrano-Afonso, Ancor
Paniagua, Nancy
author_facet Huerta, Miguel Á.
Garcia, Miguel M.
García-Parra, Beliu
Serrano-Afonso, Ancor
Paniagua, Nancy
author_sort Huerta, Miguel Á.
collection PubMed
description The pharmacological treatment of postherpetic neuralgia (PHN) is unsatisfactory, and there is a clinical need for new approaches. Several drugs under advanced clinical development are addressed in this review. A systematic literature search was conducted in three electronic databases (Medline, Web of Science, Scopus) and in the ClinicalTrials.gov register from 1 January 2016 to 1 June 2023 to identify Phase II, III and IV clinical trials evaluating drugs for the treatment of PHN. A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets: Angiotensin Type 2 Receptor (AT2R) antagonism (olodanrigan), Voltage-Gated Calcium Channel (VGCC) α2δ subunit inhibition (crisugabalin, mirogabalin and pregabalin), Voltage-Gated Sodium Channel (VGSC) blockade (funapide and lidocaine), Cyclooxygenase-1 (COX-1) inhibition (TRK-700), Adaptor-Associated Kinase 1 (AAK1) inhibition (LX9211), Lanthionine Synthetase C-Like Protein (LANCL) activation (LAT8881), N-Methyl-D-Aspartate (NMDA) receptor antagonism (esketamine), mu opioid receptor agonism (tramadol, oxycodone and hydromorphone) and Nerve Growth Factor (NGF) inhibition (fulranumab). In brief, there are several drugs in advanced clinical development for treating PHN with some of them reporting promising results. AT2R antagonism, AAK1 inhibition, LANCL activation and NGF inhibition are considered first-in-class analgesics. Hopefully, these trials will result in a better clinical management of PHN.
format Online
Article
Text
id pubmed-10455720
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104557202023-08-26 Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials Huerta, Miguel Á. Garcia, Miguel M. García-Parra, Beliu Serrano-Afonso, Ancor Paniagua, Nancy Int J Mol Sci Review The pharmacological treatment of postherpetic neuralgia (PHN) is unsatisfactory, and there is a clinical need for new approaches. Several drugs under advanced clinical development are addressed in this review. A systematic literature search was conducted in three electronic databases (Medline, Web of Science, Scopus) and in the ClinicalTrials.gov register from 1 January 2016 to 1 June 2023 to identify Phase II, III and IV clinical trials evaluating drugs for the treatment of PHN. A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets: Angiotensin Type 2 Receptor (AT2R) antagonism (olodanrigan), Voltage-Gated Calcium Channel (VGCC) α2δ subunit inhibition (crisugabalin, mirogabalin and pregabalin), Voltage-Gated Sodium Channel (VGSC) blockade (funapide and lidocaine), Cyclooxygenase-1 (COX-1) inhibition (TRK-700), Adaptor-Associated Kinase 1 (AAK1) inhibition (LX9211), Lanthionine Synthetase C-Like Protein (LANCL) activation (LAT8881), N-Methyl-D-Aspartate (NMDA) receptor antagonism (esketamine), mu opioid receptor agonism (tramadol, oxycodone and hydromorphone) and Nerve Growth Factor (NGF) inhibition (fulranumab). In brief, there are several drugs in advanced clinical development for treating PHN with some of them reporting promising results. AT2R antagonism, AAK1 inhibition, LANCL activation and NGF inhibition are considered first-in-class analgesics. Hopefully, these trials will result in a better clinical management of PHN. MDPI 2023-08-20 /pmc/articles/PMC10455720/ /pubmed/37629168 http://dx.doi.org/10.3390/ijms241612987 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Huerta, Miguel Á.
Garcia, Miguel M.
García-Parra, Beliu
Serrano-Afonso, Ancor
Paniagua, Nancy
Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials
title Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials
title_full Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials
title_fullStr Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials
title_full_unstemmed Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials
title_short Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials
title_sort investigational drugs for the treatment of postherpetic neuralgia: systematic review of randomized controlled trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455720/
https://www.ncbi.nlm.nih.gov/pubmed/37629168
http://dx.doi.org/10.3390/ijms241612987
work_keys_str_mv AT huertamiguela investigationaldrugsforthetreatmentofpostherpeticneuralgiasystematicreviewofrandomizedcontrolledtrials
AT garciamiguelm investigationaldrugsforthetreatmentofpostherpeticneuralgiasystematicreviewofrandomizedcontrolledtrials
AT garciaparrabeliu investigationaldrugsforthetreatmentofpostherpeticneuralgiasystematicreviewofrandomizedcontrolledtrials
AT serranoafonsoancor investigationaldrugsforthetreatmentofpostherpeticneuralgiasystematicreviewofrandomizedcontrolledtrials
AT paniaguanancy investigationaldrugsforthetreatmentofpostherpeticneuralgiasystematicreviewofrandomizedcontrolledtrials